NCT06314230 Australian Genomics Of Chronic Allograft Dysfunction Study
| NCT ID | NCT06314230 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Western Sydney Local Health District |
| Condition | Kidney Transplant Rejection |
| Study Type | OBSERVATIONAL |
| Enrollment | 500 participants |
| Start Date | 2012-04-26 |
| Primary Completion | 2040-01-01 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 500 participants in total. It began in 2012-04-26 with a primary completion date of 2040-01-01.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of the Australian Genomics of Chronic Allograft Dysfunction (AUSCAD) study is a single centre (Westmead Hospital), prospective, observational study, which enrols patients at time of kidney (or kidney-transplant) transplant and tracks the post transplant course. The AUSCAD study aims to generate new knowledge and improve outcomes following kidney transplantation. The primary aim is to determine whether important outcomes (including chronic rejection and graft loss) are correlated with patterns of allograft reactivity, gene expression and susceptibility profiles.
Eligibility Criteria
Inclusion Criteria: * Living or deceased donor kidney transplant candidate. * Biological sex: any * Ages: 18-75 years. * Subject must be able to understand and provide informed consent. * Deceased donor individuals where Research Consent has been obtained from the person consenting to organ donation at the time of organ retrieval. * Identifiable living donors who have received informed consent and have consented to participate in the project. Exclusion Criteria: * Presensitization in living donor recipients prior to transplantation, as determined by site-specific standards, OR positive cross match according to site specific technique in cadaveric donor recipients. * Recipients of multiple organ transplants, with the exception of kidney/pancreas transplants. * Inability or unwillingness of a participant to give written informed consent or comply with study protocol * High risk populations including pregnant women, children less than 18 years and prisoners will not be included in the study. * Non English speaking potential participants who do not understand the requirements of the study will not be included.
Contact & Investigator
Jennifer SY Li, MBBS, FRACP
✉ jennifer.li@health.nsw.gov.auFrequently Asked Questions
Who can join the NCT06314230 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 75 Years, studying Kidney Transplant Rejection. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06314230 currently recruiting?
Yes, NCT06314230 is actively recruiting participants. Contact the research team at jennifer.li@health.nsw.gov.au for enrollment information.
Where is the NCT06314230 trial being conducted?
This trial is being conducted at Westmead, Australia, Westmead, Australia.
Who is sponsoring the NCT06314230 clinical trial?
NCT06314230 is sponsored by Western Sydney Local Health District. The trial plans to enroll 500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.